Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies

被引:0
|
作者
Olejarz, Wioletta [1 ,2 ]
Sadowski, Karol [1 ,2 ,3 ]
Szulczyk, Daniel [4 ]
Basak, Grzegorz [3 ]
机构
[1] Med Univ Warsaw, Fac Pharm, Dept Biochem & Pharmacogen, PL-02097 Warsaw, Poland
[2] Med Univ Warsaw, Ctr Preclin Res, PL-02097 Warsaw, Poland
[3] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
[4] Med Univ Warsaw, Chair & Dept Biochem, PL-02097 Warsaw, Poland
关键词
CAR-T; EVs; immunotherapy; biomarkers; hematological malignancies; checkpoint inhibitors; TME; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; EPSTEIN-BARR-VIRUS; CELL-FREE DNA; CIRCULATING TUMOR DNA; NON-HODGKIN-LYMPHOMA; INHIBITORY RECEPTORS; IMMUNE MICROENVIRONMENT; GENE REARRANGEMENTS; MULTIPLE-MYELOMA;
D O I
10.3390/ijms25147743
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food and Drug Administration (FDA). Significant barriers to the effectiveness of CAR-T therapy include cytokine release syndrome (CRS), neurotoxicity in the case of Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), antigen escape, modest antitumor activity, restricted trafficking, limited persistence, the immunosuppressive microenvironment, and senescence and exhaustion of CAR-Ts. Furthermore, cancer drug resistance remains a major problem in clinical practice. CAR-T therapy, in combination with checkpoint blockades and bispecific T-cell engagers (BiTEs) or other drugs, appears to be an appealing anticancer strategy. Many of these agents have shown impressive results, combining efficacy with tolerability. Biomarkers like extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor (ctDNA) and miRNAs may play an important role in toxicity, relapse assessment, and efficacy prediction, and can be implicated in clinical applications of CAR-T therapy and in establishing safe and efficacious personalized medicine. However, further research is required to fully comprehend the particular side effects of immunomodulation, to ascertain the best order and combination of this medication with conventional chemotherapy and targeted therapies, and to find reliable predictive biomarkers.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects
    Azam Bozorgi
    Maryam Bozorgi
    Mozafar Khazaei
    Cellular Oncology, 2022, 45 : 755 - 777
  • [42] Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects
    Bozorgi, Azam
    Bozorgi, Maryam
    Khazaei, Mozafar
    CELLULAR ONCOLOGY, 2022, 45 (05) : 755 - 777
  • [43] Gene Targets of CAR-T Cell Therapy for Glioblastoma
    Wang, Chaoqun
    Li, Yuntao
    Gu, Lijuan
    Chen, Ran
    Zhu, Hua
    Zhang, Xu
    Zhang, Yonggang
    Feng, Shi
    Qiu, Sheng
    Jian, Zhihong
    Xiong, Xiaoxing
    CANCERS, 2023, 15 (08)
  • [44] Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui
    Zhou, Xuan
    Zhou, Lijuan
    Liang, Zhao
    Yang, Jilong
    Tu, Sanfang
    Li, Yuhua
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [45] Current state of CAR-T therapy for T-cell malignancies
    Luo, Liangkui
    Zhou, Xuan
    Zhou, Lijuan
    Liang, Zhao
    Yang, Jilong
    Tu, Sanfang
    Li, Yuhua
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [46] Challenges and optimal strategies of CAR T therapy for hematological malignancies
    Zhang, Yajing
    Xu, Yang
    Dang, Xiuyong
    Zhu, Zeyu
    Qian, Wenbin
    Liang, Aibin
    Han, Weidong
    CHINESE MEDICAL JOURNAL, 2023, 136 (03) : 269 - 279
  • [47] Adoptive therapy with CAR redirected T cells for hematological malignancies
    Shiqi Li
    Zhi Yang
    Junjie Shen
    Juanjuan Shan
    Cheng Qian
    Science China Life Sciences, 2016, (04) : 370 - 378
  • [48] CAR-T Cell Therapy - personalized cellular Immunotherapy in 2022
    Niebling, Janina
    Bethge, Wolfgang
    Lengerke, Claudia
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (23) : 1552 - 1561
  • [49] Adoptive therapy with CAR redirected T cells for hematological malignancies
    Li, Shiqi
    Yang, Zhi
    Shen, Junjie
    Shan, Juanjuan
    Qian, Cheng
    SCIENCE CHINA-LIFE SCIENCES, 2016, 59 (04) : 370 - 378
  • [50] Challenges and optimal strategies of CAR T therapy for hematological malignancies
    Zhang Yajing
    Xu Yang
    Dang Xiuyong
    Zhu Zeyu
    Qian Wenbin
    Liang Aibin
    Han Weidong
    中华医学杂志(英文版), 2023, 136 (03)